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function through Src-mediated signaling
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Abstract
Background: Activated microglial cells are an important pathological component in brains of patients with
neurodegenerative diseases. The purpose of this study was to investigate the effect of He-Ne (632.8 nm, 64.6 mW/cm2)
low-level laser therapy (LLLT), a non-damaging physical therapy, on activated microglia, and the subsequent signaling
events of LLLT-induced neuroprotective effects and phagocytic responses.
Methods: To model microglial activation, we treated the microglial BV2 cells with lipopolysaccharide (LPS). For the
LLLT-induced neuroprotective study, neuronal cells with activated microglial cells in a Transwell™ cell-culture system
were used. For the phagocytosis study, fluorescence-labeled microspheres were added into the treated microglial cells
to confirm the role of LLLT.
Results: Our results showed that LLLT (20 J/cm2) could attenuate toll-like receptor (TLR)-mediated proinflammatory
responses in microglia, characterized by down-regulation of proinflammatory cytokine expression and nitric oxide (NO)
production. LLLT-triggered TLR signaling inhibition was achieved by activating tyrosine kinases Src and Syk, which led
to MyD88 tyrosine phosphorylation, thus impairing MyD88-dependent proinflammatory signaling cascade. In addition,
we found that Src activation could enhance Rac1 activity and F-actin accumulation that typify microglial phagocytic
activity. We also found that Src/PI3K/Akt inhibitors prevented LLLT-stimulated Akt (Ser473 and Thr308) phosphorylation
and blocked Rac1 activity and actin-based microglial phagocytosis, indicating the activation of Src/PI3K/Akt/Rac1
signaling pathway.
Conclusions: The present study underlines the importance of Src in suppressing inflammation and enhancing
microglial phagocytic function in activated microglia during LLLT stimulation. We have identified a new and important
neuroprotective signaling pathway that consists of regulation of microglial phagocytosis and inflammation under LLLT
treatment. Our research may provide a feasible therapeutic approach to control the progression of neurodegenerative
diseases.
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Introduction
Microglia are considered to be central nervous system
(CNS)-resident professional macrophages. They perform
homoeostatic activity and mediate the innate defense
system in the normal CNS. However, localized activation
of microglia has been implicated in the pathogenesis of
several neurodegenerative disorders, such as Parkinson’s
disease (PD), Alzheimer’s disease (AD) and multiple
sclerosis [1].
In the CNS, microglia can be activated directly by pro-
ducts of microorganisms, environmental toxicants, and
protein aggregates like β-amyloid (Aβ) or indirectly after
neurodegeneration is induced [2,3]. Once microglia are
activated in neurodegenerating microenvironment, they
have macrophage-like capabilities, including phagocyt-
osis and production of inflammatory cytokine [4]. Acti-
vated microglia can phagocytose fibrillar Aβ (fAβ) or
dead cells from the CNS and can secrete different
neurotrophic factors for neuronal survival. However,
once activated, they eventually become more detrimental
by releasing proinflammatory molecules (nitric oxide
(NO) and TNF-α), thus causing secondary damage to
neurons and the surrounding cellular environment [5].
Therefore, activation of microglia has become a hallmark
of neurodegeneration. It has been debated whether neu-
roinflammation is an underling cause or a resulting con-
dition in neurodegenerative diseases.
Abundant proinflammatory cytokines and oxygen radi-
cals are presented in AD and PD brains. In PD brains,
the highest density of microglia can be found in the sub-
stantia nigra (SN). They are not only highly activated but
are also highly clustered around dystrophic dopamine
neurons, and neuromelanin pigment taken up from
degenerated dopaminergic nerve cells is characteristically
observed in SN phagocytes [3]. However, the resident
microglia always fail to trigger an effective phagocytic re-
sponse to clear Aβ deposits during AD progression [6].
Although it is indisputable that microglia-mediated neu-
roinflammation plays a key role in the pathogenesis of
neurodegenerative diseases, the relationships between
neurotoxicity and phagocytic function of the activated
microglia remain unclear.
Toll-like receptors (TLRs) are a class of conserved
receptors that serve as an important link between innate
and adaptive immunity. Microglia possess a number of
TLRs, which play an important role in microglial activa-
tion in the brain of individuals with PD and AD. Recent
studies indicated that peripheral lipopolysaccharide
(LPS) injection caused microglia-related over-expression
of TLR2 in aged mice [7], and that fAβ peptides activate
microglia via TLR2 signaling pathway [8]. Other results
show that the levels of TLR4 messenger RNA (mRNA)
are upregulated in APP transgenic mice [9], and that the
upregulation of cytokines is TLR4 dependent in an AD
mouse model [10]. Targeting TLRs may be an important
step to attenuate microglial activation in the CNS during
AD or PD pathology.
Low-level laser therapy (LLLT) can modulate a broad-
spectrum of cellular processes ranging from proliferation
to apoptosis. It has been reported that the effects of laser
irradiation on cell proliferation or inhibition are related
to light fluence [11,12]. This phenomenon of photobio-
modulation has also been widely applied in the treat-
ment of skeletal muscle regeneration [13], wound
healing [14], and skin wound care [15]. Studies have
shown that Aβ-induced cell apoptosis was significantly
diminished with light irradiation [16]. Furthermore, it
has been demonstrated that LLLT has preventive effects
on Aβ25-35-induced cell apoptosis, in which LLLT pro-
moted YAP cytoplasmic translocation and inhibited
Aβ(25–35)-induced YAP nuclear translocation [17].
Src kinases, non-receptor tyrosine kinases, are acti-
vated by oxidative events [18]. They are critically
involved in fundamental cellular processes, including cell
proliferation, migration and phagocytosis [19]. Recently,
Han et al. observed that CD11b negatively regulated
TLR-triggered inflammatory responses in macrophage
by increasing Cbl-b-mediated degradation of MyD88
and TRIF, which depended on Src-Syk activation [20].
The involvement of LLLT-induced Src activation at rela-
tively high laser doses in cells has been identified [21].
Since microglia can be beneficial by phagocytosing Aβ
or harmful by secretion of neurotoxins, we hypothesized
that Src may be involved in microglial functional regula-
tion under LLLT. Thus, the effect of LLLT on microglia
functions needs to be clarified in developing strategies to
slow or prevent the progression of AD or other
inflammation-mediated neurodegenerative diseases.
In this study, we investigated the effects of LLLT on
LPS-activated microglia-induced neurotoxicity using
microglia-like BV-2 cells and neuron-like neuroblastoma
SH-SY5Y cells. We also examined the phagocytic effects
of microglia and the interaction between microglial
phagocytosis and neuroinflammation during LLLT. Our
results suggested that LLLT could induce Src activation
for neuroprotection by attenuating microglia-mediated




The following reagents were used: LPS purified from
Salmonella typhimurium (Sigma-Aldrich, St. Louis, MO,
USA) to stimulate microglia; wortmannin and LY290042
(Sigma-Aldrich) to inhibit phosphatidylinositol 3-kinase
(PI3K); API-2 (Sigma-Aldrich) to inhibit Akt; SMT
((C2H6N2S)2H2SO4) (Sigma-Aldrich) to inhibit iNOS;
PTIO (Beyotime Biotech., Haimen, Jiangsu, China) to
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scavenge NO; FITC-phalloidin (Sigma-Aldrich) to stain
F-actin; latex beads (Sigma-Aldrich) to detect microglial
phagocytosis; and propidium iodide (PI), CFSE, PKH26
and PKH67 (Sigma-Aldrich) to stain cells. Dual Lucifer-
ase Reporter Gene Assay kits were purchased from
Beyotime Biotechnology and Nuclear/Cytosol Fraction-
ation Kits were purchased from Biovision (Cambridge
BioScience, Cambridge, U.K.).
The following antibodies were used: rabbit anti-
MyD88, rabbit anti-GAPDH, rat-anti-Histone 3, rabbit
anti-iNOS, and rat anti-β-actin. All were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-
bodies specific for phosphorylated Syk Y519/520, Src
Y416, FAK Y397, FAK Y861, Akt ser473, and Akt
Thr308 were all purchased from Cell Signaling Technol-
ogy (Beverly, MS, USA). Rabbit anti-Akt, mouse anti-
FAK and rabbit anti-Rac1 antibody were obtained from
Santa Cruz Biotechnology.
In addition, we used jetPEI™-macrophage transfecting
reagent (Invitrogen, Carlsbad, CA, USA) to transfect
plasmid DNA into cells and the cells were examined 36
to 48 h after transfection. The plasmid of pRaichu-Rac1
was kindly supplied by Dr. Michiyuki Matsuda.
Rac1Q61L, Rac1T17N and wt Rac1 were purchased
from Upstate Biotechnology (Lake Placid, NY, USA). Dr.
Dianne Cox kindly provided the shRNA Syk and scram-
ble shRNA. GFP-FRNK was a gift from Dr. Thomas
Parsons. Dr. X. Shen (Institute of Biophysics, Chinese
Academy of Sciences) kindly provided the pNF-κB-Luc.
Dr. David A. Geller kindly provided the iNOS-Luc, and
the pRL-TK was purchased from Promega (Mannheim,
Germany).
Cell culture
Murine microglia-like cell line BV-2 was maintained in
Dulbecco’s modified Eagle’s medium (DMEM) with 15%
heat-inactivated fetal calf serum (FCS), penicillin (100
units/ml), and streptomycin (100 μg/ml) in 5% CO2,
95% air at 37°C in a humidified incubator. To generate
activated microglia, we stimulated cells LPS alone
(100 ng/ml) or with different concentrations of inhibi-
tors before LLLT treatment.
Primary microglia were isolated from postnatal day 1
to day 2 mouse brains (C57BL/6 J), as described previ-
ously [22]. Cells were cultured in DMEM/F12, with 20%
fetal bovine serum (FBS), penicillin (100 units/ml), and
streptomycin (100 μg/ml) in 5% CO2, 95% air at 37°C in
a humidified incubator. Astrocytes were separated from
the microglial cultures using a mild trypsinization proto-
col described by Saura et al. [23].
The present study was performed in accordance with
the guidelines of the Guide for the Care and Use of La-
boratory Animals (Institute of Laboratory Animal
Resources, Commission on Life Sciences, National
Research Council. Washington, DC: National Academy
Press, 1996.); it was approved by the Institutional Ani-
mal Care and Use Committee of our university (South
China Normal University, Guangzhou, China). The
human neuroblastoma cell line SH-SY5Y was cultured
in DMEM containing 10% heat-inactivated FBS, penicil-
lin (100 units/ml), and streptomycin (100 μg/ml) in 5%
CO2, 95% air at 37°C in a humidified incubator.
LLLT treatment
The experiment was conducted as described in our pre-
vious work [24]. After 36 to 48 h of serum starved with
0.5% FBS, the microglial cells were irradiated with He-
Ne laser (632.8 nm, 64.6 mW/cm2, HN-1000), (Laser
Technology Application Research Institute Co., Ltd.,
Guangzhou, China) for 0.8, 1.33, 2.66, 5.32, 6.66, or
13.33 min in the dark, with the corresponding fluences
of 3, 5, 10, 20, 25, and 50 J/cm2 respectively.
Transient transfection and luciferase activity
Transient transfection of cells was performed using
jetPEI™-macrophage transfecting reagent according
to manufacturer’s instructions (Polyplus-transfection,
Strasbourg, France). For luciferase activity assay,
microglial cells in a 48-well plate (5× 104 cells/well)
were incubated with plasmids containing 0.3 μg of
pNF-κB or iNOS reporter luciferase plasmid. We used
pRL-TK as an internal control of transfection efficiency.
To correct for differences in transfection efficiency, each
group of cells was transfected with 30 ng of pRL-TK
and incubated overnight. The ratio of luciferase activity to
pRL-TK activity in each sample served as a measure of
normalized luciferase activity. Forty-eight hours after co-
transfection, the cells were incubated with 100 ng/ml LPS
for 12 h, and then cells were treated with LLLT and cul-
tured for another 6 h. Cell extracts were prepared for de-
termination of luciferase activity using Dual Luciferase
Reporter Gene Assay Kit according to the manufacturer’s
instructions. Luciferase assays were performed on a 96-
well plate reader (Tecan Infinite M200, Tecan Group Ltd,
Mannedorf, Switzerland) for 20 s. Results are expressed as
the ratio of luciferase to pRL-TK (mean±SEM).
Confocal laser scanning microscopy (LSM)
Fluorescent emission from FITC was monitored confo-
cally using a commercial laser scanning microscope
(LSM 510/ConfoCor2) combination system (Zeiss, Jena,
Germany) equipped with a Plan-Neofluar 40×/1.3 NA
Oil DIC objective. FITC fluorescence was excited at
488 nm with the Ar-Ion laser (reflected by a beam split-
ter HFT 488 nm), and the fluorescence emission was
recorded through a 500 to 530 nm IR band-pass filter.
For intracellular measurements, the desired measure-
ment position was chosen in the LSM image. To
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quantify the results, the average emission intensities
from desired measurement positions were processed
with Zeiss Rel3.2 image processing software (Zeiss, Jena,
Germany).
Nitric oxide measurement
Nitric Oxide (NO) production in microglia was detected
with the fluorescent probe DAF-FM DA. DAF-FM DA is
a cell permeable fluorescent probe for the detection of
NO. It can passively diffuse across cellular membranes;
once inside cells, it is deacetylated by intracellular
esterases to become DAF-FM [25]. DAF-FM is essen-
tially non-fluorescent until it reacts with NO. With exci-
tation/emission maxima of 495/515 nm, the fluorescent
intensity and images of DAF-FM can be detected by a
96-well plate reader and by confocal laser microscopy,
respectively.
Western blot analysis
Expressions of proteins were quantified by western blot
analysis. After individual incubations, cell proteins were
extracted in lysis buffer (50 mM Tris–HCl pH 8.0,
150 mM NaCl, 1% TritonX-100, 100 μg/ml PMSF) sup-
plemented with protease inhibitor cocktail set I for
60 min on ice. After centrifugation (4°C, 12,000 rpm,
20 min), the resulting lysates were resolved on 8% SDS-
PAGE Bis-Tris gels (30 mg/lane; Invitrogen, Life Tech-
nologies, Grand Island, NY, USA) and transferred to
nitrocellulose membranes (Millipore, Bedford, MA,
USA). The membranes were blocked in TBST (10 mM
Tris–HCl, pH 7.4, 150 mM NaCl, 0.1% Tween-20) con-
taining 5% non-fat milk and then incubated with a desig-
nated primary antibody and a secondary antibody. The
signals were detected with an ODYSSEY™ Infrared Im-
aging System (Li-Cor, Lincoln, NE, USA). The intensity
of the western blot signals was quantitated using ImageJ
software (NIH, Bethesda, MD, USA), and the densitom-
etry analyses are presented as the ratio of protein/β-actin
protein, and are compared with controls and normalized
to 1.
Rac1 activity assay
We measured Rac1 activity in LLLT treated microglial
cell lysate using Rac1 Activation Assay Kit (Upstate Bio-
technology, Lake Placid, NY, USA) according to the
manufacturer’s instructions.
Microglia cytotoxicity assay
Cytotoxicity of microglial cells was assessed using a
Transwell™ cell-culture system or a coincubation system.
In the Transwell™ cell-culture system, 5 × 106 microglial
cells in 1 ml medium were added to the upper chamber
of 6-well Transwell™ plates with 0.4-μm pores (Costar,
Corning Inc., NY, USA), and cells were incubated with
100 ng/ml LPS for 10 h at 37°C. After being washed with
PBS, target SH-SY5Y cells were resuspended at 1 × 106
cells/mL and labeled with 1 mM carboxyfluorescein dia-
cetate succinimidyl ester (CFSE) (Molecular Probes
Europe, Leiden, The Netherlands) for 8 min at 37°C.
The labeling reaction was quenched by the addition of
cold DMEM containing 10% FBS. After washing with
PBS, the CFSE-labeled target cells in 1.5 ml medium
were added to the lower chamber of Transwell™ plates.
When microglia were exposed to light, we took the
upper chamber in a new 6-well plate for LLLT. Immedi-
ately thereafter, the 6-well plate was replaced by the
lower Transwell™ chamber with SH-SY5Y cells to micro-
glial cells at a ratio of 1:8 at 37°C in a humidified atmos-
phere of 5% CO2. By using this procedure, we prevented
the direct impact of LLLT on the neuronal cells. In co-
culture conditions, microglial cells were treated with
LLLT. After 24 h incubation, cells in the lower chamber
were harvested, propidium iodide (PI) was added to stain
dead cells, and all samples were directly analyzed by
fluorescence-activated cell sorting (FACS). Target cells
killed by microglial cells were represented by the cell
population showing double-positive staining for CFSE
and PI.
In a coincubation system, 5 × 106 PKH26 (red)-labeled
microglial cells with 100 ng/ml LPS in 1 ml medium
were added to the 6-well plate. After 10 h incubation,
the cells were treated with LLLT. Then 1 × 106 PKH67
(green)-labeled SH-SY5Y cells in 1.5 ml medium were
added to the treated microglial cells. After 24 h coincu-
bation, mix-cultured cells were harvested and PI was
added to stain dead cells. All samples were analyzed by
FACS. Target cells killed by microglial cells were repre-
sented by the cell population showing double-positive
staining for PKH67 and PI/PKH26. Based on the evi-
dence that phagocytes engulf dead cell corpses but not
living cells, the dead PKH67-labled SH-SY5Y cells pha-
gocytosed by PKH26-labled microglia can also be repre-
sented by the cell population showing double-positive
staining for PKH67 and PKH26/PI.
Phagocytosis assay
Microglial cells were collected and 1 × 105 cells were
cultured in 35 mm glass-bottomed dishes overnight.
The cells were incubated in the presence or absence of
the inhibitors, and then subjected to LLLT treatment.
The fluorescent microspheres, as a marker of phagocyt-
osis, were added to the treated cells at indicated time
points after having been washed in PBS containing 0.1%
BSA. Cells were then fixed with 4% paraformaldehyde,
and three random fields of cells (>100 cells) were
counted under a confocal microscope.
Phagocytic efficiency was determined by using the
method of Pan et al. [26]. Briefly, the phagocytic
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efficiency was based on a weighted average of ingested
microspheres per cell. The number of cells containing
microspheres, the number of microspheres per cell, and
the total number of cells were counted respectively.
Phagocytic efficiency was calculated:
%ð Þ ¼ 1 X1þ 2 X2þ 3 X3:þ n Xnð Þ=
 total number of cellsð Þ  100%
where Xn represents the number of cells containing n
microspheres (n = 1, 2, 3, up to a maximum of 6 points
for more than 5 microspheres ingested per cell).
Phalloidin staining
The treated cells were rinsed with PBS before being
fixed in 3.7% formaldehyde and washed again in PBS.
The cells were then incubated at room temperature with
0.1% Triton X-100 buffer for 5 min and washed again in
PBS. FITC-phalloidin (1:50 diluted in PBS) was added to
the cover slips and incubated at room temperature pro-
tected from light for 30 min. The cover slips were
mounted on glass slides. The FITC-labeled phalloidin
was viewed under a confocal microscope.
Quantitative measurement of F-actin
To assess the total F-actin content in microglial cells,
microglia were treated with LPS for indicated time peri-
ods. The reaction was stopped by the addition of formal-
dehyde (3.7% final, V/V) for 15 min at room
temperature. The fixed cells were then permeabilized
with 10 mM imidazole, 40 mM KCl, 10 mM EGTA
(ethylene glycol tetraacetic acid), 1 mM MgCl2, and 1%
Triton X-100 at 4°C for 15 min. F-actin was then stained
with FITC-phalloidin (Molecular Probes™, Life Technolo-
gies, Grand Lake, NY, USA) for 2 h at room temperature.
After the cells were washed with PBS, F-actin-bound
FITC-phalloidin was extracted with methanol. The
extracts were centrifuged to remove any insoluble ma-
terial, and relative fluorescence was measured using a
96-well plate reader with excitation and emission wave-
lengths set at 465 and 535 nm, respectively. The F-actin
ratio was calculated as:
F actin in treated cells backgroundð Þ=
 F actin in indicated cells expression wildðð
 type Rac1 cells in Figure 5B or untreated
 cells in Figure 6EÞ  backgroundÞ
Statistical analysis
Data are from one representative experiment among at
least three independent experiments and are expressed
as the mean± SEM. Significant differences between
groups were compared using the one-way ANOVA
procedure followed by Student’s t tests using SPSS soft-
ware (SPSS Inc., Chicago, IL, USA) and the differences
were considered statistically significant at P <0.05.
Results
Effects of LLLT on LPS-activated microglia-induced
cytotoxicity
To examine the anti-inflammatory effect of LLLT on
LPS-activated microglia, we used neuronal cell line SH-
SY5Y, which is an in vitro model to mimic responses of
neurons. As shown in Figure 1A, cell death was attenu-
ated by treatment of LLLT (20 J/cm2), and the relative
death rate (LPS treated cells - LPS + LLLT treated cells)
was lowered by LLLT to a similar extent at both 24 h
and 48 h. Therefore, we used 24 h as the optimal time in
the following microglial cytotoxicity experiments.
To determine the optimal dose of LLLT, LPS-activated
BV-2 cells or primary microglia were treated by LLLT of
different doses (3, 5, 10, 20, 25 or 50 J/cm2) and co-
cultured with SH-SY5Y cells for 24 h. Microglia-
mediated cytotoxicity was evidently reduced by LLLT in
a dose-dependent manner (Figure 1B). While inducing
the lowest microglia-mediated neurotoxicity, laser irradi-
ation with a dose of 25 or 50 J/cm2 caused a slight con-
traction of microglial cells in some cases (data not
shown), probably due to the toxic effect of laser irradi-
ation with high doses. Therefore, unless stated other-
wise, we used 20 J/cm2 as the optimal dose in the
following experiments.
Since LPS led to abundant NO and inducible NO syn-
thase (iNOS) induction in microglia, next iNOS was
used to examine whether LLLT are capable of attenuat-
ing such proinflammatory molecule in microglia. As
expected, LLLT inhibited the iNOS protein expression in
a dose-dependent manner (Figure 1C, D). NO accumula-
tion in BV-2 cells was also observed under LLLT using
fluorescent probe DAF-FM DA (data not shown).
LLLT-mediated neuroprotection requires Syk-dependent
degradation of MyD88
Next we explored possible signal-transduction pathways
in attenuating proinflammation response in LPS-
activated microglia after LLLT treatment. Until recently,
most studies suggested that Src and Syk tyrosine kinases
were important in regulating TLR signaling [20,27].
Therefore, we adopted the RNA interference (RNAi)
technique to investigate the role of Syk in TLR-mediated
inflammatory response in microglia under LLLT. Knock-
down of Syk by shRNA significantly suppressed LLLT-
mediated microglial neuroprotective effects, indicating
that Syk activation contributed to the TLR-targeted in-
flammatory response (Figure 2A).
One important finding by Han and colleagues was
that CD11b-mediated anti-inflammatory response was
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dependent on Src-mediated Syk activation by depho-
sphorylating TLRs and their adaptors [20]. To deter-
mine whether LLLT could inhibit LPS-activated,
microglia-induced cell death due to Src activation,
LPS-activated BV-2 cells were treated with LLLT (3, 5,
10, 20, 25 or 50 J/cm2). The phosphorylation level of
Src at Tyr416, which was indicative of Src activation,
was evidently increased at 5 min by LLLT in a dose-
dependent manner (Figure 2B, C). Pretreatment of cells
with PP1, a specific inhibitor of Src kinase, significantly
inhibited the activation of Src and iNOS expression by
various doses of LLLT (as shown in Figure 1C and D).
To determine whether LLLT-mediated neuroprotec-
tion is required for Syk-mediated adaptors degradation,
we examined the expression of MyD88 and iNOS using
shRNA-Syk by western blot. Notably, more MyD88 and
iNOS were detected in Syk-knockdown microglia than
in control cells (Figure 2D and E). Because tyrosines 519
and 520 are located in the activation loop of the Syk kin-
ase domain and phosphorylation of Tyr519/520 is essen-
tial for Syk function, we measured Syk activation by
detecting tyrosine phosphorylation at the residues 519/
520. Pretreatment of BV-2 cells with PP1 resulted in in-
hibition of Syk activation and failed to attenuate MyD88
and iNOS expression (Figure 2D-F). In addition, both
NF-κB- and iNOS-dependent gene reporter assays in
BV-2 cells (data not shown) and primary microglia
revealed that LLLT-mediated neuroprotective effect was
dependent on Src/Syk-mediated down-regulation of
TLRs signal pathway (Figure 2G). The western blot
results clearly show that translocation of p65 into the
BV-2 cells’ nucleus is reduced after LLLT treatment
(Figure 2H-I). Furthermore, after LLLT treatment, the
TNF-α production was increased drastically when Src or
Syk was blocked (Figure 2J). These results suggested that
Syk was functional in microglia and that LLLT-mediated
anti-inflammatory signal in microglia was via Src/Syk.
LLLT-mediated Syk activation does not require FAK
Src forms a complex with FAK which can phosphorylate
other substrates and trigger multiple intracellular signal-
ing pathways that induce different cellular responses
Figure 1 Effects of LLLT on LPS-activated microglial cells. SH-SY5Y cells were cultured (A) in the presence of LLLT-treated (20 J/cm2)
LPS-activated BV-2 cells for 12, 24, and 48 h or (B) in the presence of the indicated doses of LLLT-treated BV-2 cells or primary microglia for 24 h.
(A and B) Effector cells (microglia) were incubated with target cells (SH-SY5Y) at an E:T ratio of 8:1. After incubation, target cells that were double
positive for CFSE and PI were analyzed by flow cytometry (n = 4; *P <0.05 and **P <0.05 versus corresponding control cells, #P <0.05 versus
indicated cells). (C) BV-2 cells pretreated with or without PP1, then subjected to LLLT treatment, followed by western blot analysis of LPS-
activated BV-2 cells received different doses of LLLT treatments to detect protein levels of iNOS. (D) Quantitative analysis of iNOS protein levels in
treated cells. Data represent mean± SEM (n = 4; *P <0.05 versus control cells, #P <0.05 versus indicated cells). CFSE, carboxyfluorescein diacetate
succinimidyl ester; iNOS, inducible nitric oxide synthase; LLLT, low-level laser therapy; LPS, lipopolysaccharide; PI, propidium iodide.
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[28]. We examined FAK phosphorylation on the Src-
dependent tyrosine residue 861 (pY861), which is a
well-characterized Src-dependent site, as well as the
autophosphorylation site of FAK, pY397. Our results
showed elevated levels of pY861-FAK in all LLLT-treated
microglia except for the cells pretreated with PP1
(Figure 3A and B). However, cells expressing FAK related
non-kinase (FRNK), an endogenous inhibitor of FAK,
failed to show LLLT-induced Src-mediated neuroprotec-
tive effect on SH-SY5Y neuronal cells (Figure 3C). It
appears that although FAK is activated under LLLT, it’s
not involved in the downstream of Syk activation. This
observation was further supported by western blot ana-
lysis in both BV-2 cells and primary microglia
(Figure 3D).
Effects of LLLT on LPS-activated microglial phagocytic
activity
Given that phagocytosis is the process that results in the
uptake of large particles (≥1 μm) by an actin-based
mechanism, we ask whether FAK activation is due to
microglial phagocytic activity after LLLT. Microglial
phagocytosis was monitored by the internalization of
fluorescent microspheres. Such microbeads have been
used previously to investigate signaling in phagocytic
cells [29].
LLLT enhanced microglial phagocytic function in a
time-dependent manner (Figure 4A, B). For phagocytosis
analysis, a control group (LPS treated group) subtraction
was performed. Exposure of BV-2 cells to LLLT at a dose
of 20 J/cm2 for 30 min produced the maximal phago-
cytic response, in which the relative percentage of pha-
gocytized cells and that of phagocytic efficiency were
34.03 ± 5.1% and 145.48 ± 17.1%, respectively. The
enhanced phagocytic activity was further demonstrated
in primary microglia at 30 min after LLLT treatment
(Figure 4C). Since actin assembly provides the driving
force for particle engulfment by allowing the extension
of membrane pseudopods that wrap the particle and
eventually close to form a phagosome, we also observed
F-actin recruitment and cupping around beads in BV-2
cells. LLLT markedly enhanced microglial phagocytosis,
as shown in Figure 4D.
Actin-based phagocytosis is a Rac1-dependent process
Rac1 activation, by cycling between GDP-bound inactive
and GTP-bound active conformations, has been shown to
induce actin polymerization and is essential for cell phago-
cytosis [30-32]. We explored the role of Rac1 in LLLT-
mediated microglial phagocytosis. As shown in Figure 5A,
LLLT induced a significantly actin polymerization in BV-2
cells.
To study the effects of Rac1 activity on actin
polymerization, we quantified F-actin content in LPS-
activated primary microglia that were transfected with
different Rac1 constructs under LLLT treatment. It’s
clearly evident, as shown in Figure 5B, that a constitu-
tively activated form of Rac1 (Rac1Q61L) induced a
higher level of actin polymerization than cells trans-
fected with wild-type Rac1, whereas a dominant negative
form of Rac1 (Rac1T17N) markedly suppressed actin
polymerization. In addition, the involvement of Rac1 ac-
tivation after LLLT treatment was also confirmed by
using a Raichu fluorescence resonance energy transfer
(FRET)-based biosensor (data not shown).
In order to characterize the temporal effects of LLLT
on Rac1 activation in BV-2 cells, we measured Rac1 ac-
tivity from 2 min to 30 min. Rac1 was significantly acti-
vated within 2 min after LLLT and declined after 15 min
(Figure 5C and D).
LLLT-induced Rac1 activation is mediated by Src-
dependent activation of PI3K/Akt signaling pathway
Activation of PI3K/Akt signaling pathway has been cor-
related with macrophage phagocytosis [33]. To address
whether Rac1 activation is mediated by PI3K/Akt signal-
ing pathway, LPS-activated BV-2 cells were pretreated
with wortmannin, which covalently inactivates the PI3K
catalytic site, and with API-2, an Akt inhibitor. Both
wortmannin and API-2 markedly reduced Rac1 activity
(See figure on previous page.)
Figure 2 LLLT-mediated neuroprotective effects dependent on Src/Syk-induced TLRs signal inhibition. (A) Effects of Syk on microglial-
induced cytotoxicity after LLLT (20 J/cm2) treatment. (n = 4; *P <0.05 and **P <0.05 versus corresponding control cells, #P <0.05 versus indicated
cells). (B) Representative western blot analysis of LPS-activated BV-2 cells (pretreated with or without 10 μM PP1) received different doses of LLLT
treatments to detect phospho-Tyr416-Src. (C) Quantitative analysis of the levels of phosphor-Tyr416-Src in treated cells. Data represent
mean± SEM (n = 4; *P <0.05 versus control cells, #P <0.05 versus indicated cells). (D-F) Representative western blot and quantitative analysis of
total Syk, phospho-Tyr519/520-Syk, total MyD88, and total iNOS in treated cells. Data represent mean± SEM (n = 4; *P <0.05 and **P <0.05 versus
corresponding control cells, #P <0.05 versus indicated cells). (G) Relative NF-κB and iNOS luciferase activities in primary microglia after LLLT
treatment. Data represent mean± SEM (n = 6; *P <0.05 and **P <0.05 versus corresponding control cells, #P <0.05 versus indicated cells). (H)
Representative western blot analysis of p65 in cytoplasmic (Cytosol) and nuclear fractions from lysates of BV-2 cells after LLLT treatment. (I)
Quantitative analysis of p65 protein levels in treated cells. Data represent mean± SEM (n = 4; *P <0.05 and **P <0.05 versus corresponding control
cells, #P <0.05 versus indicated cells). (J) TNF-α secretion by microglia under different treatments. Data represent mean± SEM (n = 6; *P <0.05 and
**P <0.05 versus corresponding control cells, #P <0.05 versus indicated cells). iNos, inducible nitric oxide synthase; LLLT, low-level laser therapy;
LPS, lipopolysaccharide; TLR, toll-like receptor.
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after LLLT treatment (Figure 6A and B). Cells pretreated
with PP1 reduced Rac1 activity, similar to wortmannin.
Interestingly, cells transfected with FRNK, a naturally
occurring inhibitor of FAK signaling, only caused partial
inhibition of Rac1 activity. These results suggested that
Src/FAK were involved in Rac1 activation and PI3K/Akt
acted as an upstream event of Rac1.
We next investigated phosphorylation levels of Akt in
BV-2 cells under LLLT (20 J/cm2) treatment. Date
shown in Figure 6C and 6D revealed that LLLT caused
significant induction of phospho-Thr308-Akt and phos-
pho-Ser473-Akt, which were positively correlated with
irradiation time, whereas total levels of Akt were un-
changed. PP1 reduced the levels of both phospho-
Thr308-Akt and phospho-Ser473-Akt. These results
suggested that LLLT induced activation of the PI3K/
Akt signaling pathway.
To determine whether the inhibition of PI3K/Akt sig-
nal in microglial cells prevents actin polymerization, we
quantified F-actin content in primary microglia that
were treated by LPS with or without wortmannin or
API-2 after LLLT treatment. The presence of wortman-
nin or API-2 inhibited the F-actin accumulation
(Figure 6E). PI3K inhibitor wortmannin or Akt inhibitor
API-2 markedly suppressed BV-2 microglial phagocyt-
osis (Figure 6F). Taken together, our results suggested
that Src/PI3K/Akt pathway was required in the LLLT-
induced Rac1 activation.
Proinflammatory cytokines attenuate microglial
phagocytosis
Proinflammatory cytokines, such as NO and TNF-α, are
capable of attenuating microglial phagocytosis by indu-
cing actin depolymerization [34,35]. We further ask
whether an LLLT-induced neuroprotective effect is posi-
tively correlated with microglial phagocytic activity. In
BV-2 cells pretreated with SMT, an iNOS inhibitor, it’s
clearly evident that inhibition of NO production signifi-
cantly increased microglial phagocytic activity (Figure 6F).
We also determined the percentage of phagocytized cells
and that of phagocytic efficiency in BV-2 cells pretreated
with Carboxy-PTIO, a NO scavenger, after LLLT
Figure 3 Role of FAK in Syk-mediated neuroprotective effects under LLLT treatment. (A) LPS-activated BV-2 cells pretreated with or
without 10 μM PP1, followed by LLLT treatment. Western blot analysis of the treated cells was performed to detect phospho-Ty861-FAK,
phospho-Tyr397-FAK, and total FAK at indicated time. (B) Quantitative analysis of the levels of phospho-Ty861-FAK, phospho-Tyr397-FAK, and total
FAK in treated cells. Data represent mean± SEM (n = 4; *P <0.05 and **P <0.05 versus corresponding control cells, #P <0.05 versus indicated cells).
(C) BV-2 cells were transfected with GFP-FRNK (FRNK, an endogenous inhibitor of FAK). G418-resistant cells were collected for LPS (100 ng/ml)
stimulation and LLLT (20 J/cm2) treatment. Immediately thereafter, SH-SY5Y cells were subjected to microglia cytotoxicity assay as previous
described. Data represent mean± SEM (n= 4; *P <0.05 versus control cells, #P <0.05 versus indicated cells). (D) Western blot analysis of the
transfected cells received LPS stimulation and LLLT treatment to detect phospho-Tyr397-FAK, phospho-Tyr519/520-Syk, total MyD88, and total
iNOS. Data were the representative graph (n = 4). iNOS, inducible nitric oxide synthase; LLLT, low-level laser therapy; LPS, lipopolysaccharide.
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treatment (Figure 7A, B). The results are consistent with
the observations that are shown in Figure 6F.
Previous studies indicated that inhibition of microglial
phagocytosis was sufficient to prevent inflammatory
neuronal death [36]. To address whether LLLT-induced
microglial phagocytic activity can trigger potent proin-
flammation and subsequently overrides its anti-
inflammatory effects, microglial cytotoxicity assay was
performed. PKH26-labled, LPS-activated BV-2 cells or
primary microglia were treated by LLLT and then mix-
cultured with PKH67-labled SH-SY5Y neuronal cells for
24 h. Compared with the results in Transwell™ cell-
culture system, LLLT had a slight enhancement effect on
neuron death (Figure 7C and D).
Discussion
In the present study, we found a regulatory role of LLLT
for microglial functions. Our major findings showed that
LLLT significantly reduced LPS-activated microglia-
induced neuronal cell death. In LPS-activated microglia-
like BV-2 cells, LLLT attenuated inflammation cytokine
TNF-α, decreased the production of NO, down-
regulated overexpression of iNOS, and caused MyD88
degradation. Another important observation was that
Figure 4 Effects of LLLT on phagocytic function of activated microglial cells. (A and B) BV-2 cells with or without LLLT (20 J/cm2) treatment
incubated with microspheres for indicated time. (A) Quantification of LLLT-mediated microglial phagocytosis; (B) The number of microspheres
taken up per BV-2 cell (n = 4; #P <0.05 versus indicated cells). (C) LLLT-mediated phagocytic response in primary microglia at 30 min. (n = 4;
*P <0.05 and **P <0.05 versus corresponding control cells, #P <0.05 versus indicated cells). (D) Fluorescent images of the distinct microglial
phagocytosis. Microglial BV-2 cells with or without LPS or LPS plus LLLT treatment. Immediately thereafter, fluorescent microspheres (red) were
added for 30 min. Cells were then fixed with 4% paraformaldehyde and stained with FITC-labeled phalloidin to visualize F-actin (green) and
confocal Z-stacks were acquired. Images shown are representative of approximately 100 cells. Bar = 10 μm. LLLT, low-level laser therapy; LPS,
lipopolysaccharide.
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microglial phagocytosis was improved after LLLT treat-
ment, characterized by an increase in Rac1 activity, actin
polymerization and the ability of the microbeads to
phagocytize. Moreover, we found that LLLT could in-
duce the enhancement of microglial phagocytic activity
by a Src-dependent PI3K/Akt pathway. Understanding
the mechanism and functional significance of LLLT-
induced microglia-mediated phagocytosis and neuroin-
flammation may lead to new neurotherapies.
AD is known to be associated with neuroinflammation
and activated microglia. Uncontrolled and excessive acti-
vation of microglia is capable of releasing various poten-
tially cytotoxic molecules such as NO, oxygen radicals,
and proinflammatory cytokines such as TNF-α, IL-1β,
and IL-6 [37,38]. Chronic neuroinflammation induced
by excessive production of these neurotoxic molecules
plays an important role in the degenerative process of
AD patients. LPS acts as a potent stimulator of microglia
and has been used to study the inflammatory process in
the pathogenesis of AD and anti-inflammatory therapy
for AD treatment. Evidence from some rat models
showed that microglia were activated immediately after
LPS injection. Significant elevations of cluster differenti-
ation marker CD45, glial fibrillary acidic protein (GFAP),
scavenger receptor A (SRA), and Fcγ receptor mRNA
were seen after 24 h [39]. LPS-induced inflammation also
exacerbates phospho-tau pathology in rTg4510 mice [40].
TLRs play a key role in microglia-mediated neuroin-
flammation. Previous studies revealed that integrin
CD11b could be activated by TLR-triggered inside-out
signaling, and then negatively regulated TLR-induced in-
flammatory response by promoting degradation of their
adaptors [20]. Similar to the results of the present study,
Mallard et al. demonstrated that microglial MyD88 sig-
naling played an important role in regulating acute neur-
onal toxicity and MyD88 deficiency attenuated release
of microglial proinflammatory cytokines following LPS
exposure [41].
Figure 5 LLLT-mediated microglial phagocytosis is a Rac-1-dependent actin-based process. (A) LPS-activated BV-2 cells pretreated with or
without wortmannin (100 nM) under LLLT treatment. 30 min after incubation, cells were fixed with 4% paraformaldehyde and stained with FITC-
labeled phalloidin to visualize F-actin (green), and confocal Z-stacks were acquired. Images shown are representative of approximately 100 cells.
Bar = 50 μm. (B) Primary microglia transfected with Rac1Q61L, Rac1T17N or wt-Rac1. G418-resistant cells were collected for further LPS stimulation.
30 min after LLLT (20 J/cm2) treatment, total F-actin was stained using FITC-phalloidin and measured using a 96-well plate reader. F-actin ratio
was calculated as (F-actin in transfected cells - background)/(F-actin in wt-Rac1 transfected cells - background). Data represent mean± SEM
(n = 6). (C) Representative western blot analysis of LLLT-treated LPS-activated BV-2 cells to detect GTP-Rac1 and total Rac1. (D) Quantitative
analysis of the levels of GTP-Rac1 and total Rac1 in treated cells. Data represent mean± SEM (n = 4; *P <0.05 versus control cells). LLLT, low-level
laser therapy; LPS, lipopolysaccharide.
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Much attention has been paid to therapeutic strat-
egies aimed at controlling microglia-mediated neurotox-
icity. LLLT is a non-thermal irradiation using light in
visible to near infrared range which has been used clin-
ically to accelerate wound healing and reduce pain and
inflammation in a variety of pathologies [42,43]. More-
over, transcranial LLLT has shown good effects on
treatment of stroke, traumatic brain injury, and neuro-
degenerative disease [44]. Although in many pre-clinical
and clinical studies the 810-nm NIR light has been used
Figure 6 (See legend on next page.)
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for nerve repairs [45-47], the effects of laser irradiation
with different wavelengths on microglial activation re-
main unclear. Studies had shown that the 632.8-nm
laser had advantages over other wavelengths in treating
neurological diseases [48,49]. Therefore, LLLT using the
632.8-nm laser may have high clinical relevance. Re-
cently, it has been debated whether He-Ne laser light
can activate a number of signaling pathways including
MAPK/ERK, Src, Akt and RTK/PKCs signaling pathway
[11,21,24,50].
We explored the role of Src activation involved in
LPS-activated microglia after LLLT treatment. In our
experiments, we demonstrated that LLLT triggered a sig-
nificant activation of Src in LPS-activated BV-2 cells
(Figure 1C). In addition, the activation of Syk triggered
by LLLT was Src-dependent. LLLT-mediated Src/Syk ac-
tivation could significantly decrease MyD88 and iNOS
expression (Figure 2B). Blockade of Src activation or
knockdown of Syk negatively affects neuronal survival
under LLLT treatment (Figure 2A).
(See figure on previous page.)
Figure 6 Src regulates Rac1-dependent microglial phagocytosis through PI3K/Akt pathway. (A) LPS-activated BV-2 cells pretreated with or
without PP1 (10 μM), wortmannin (100 nM), or API-2 (5 μM), followed by LLLT (20 J/cm2) treatment. Cells stably transfected with GFP-FRNK were
also collected for LPS stimulation and LLLT treatment. Western blot analysis of the treated cells was performed to detect GTP-Rac1 and total Rac1
at 10 min. Data were the representative graph. (B) Quantitative analysis of the levels of GTP-Rac1 and total Rac1 in treated cells. Data represent
mean± SEM (n = 4; *P <0.05 versus control cells,). (C) LPS-activated BV-2 cells pretreated with or without PP1, wortmannin, or API-2, followed by
LLLT (20 J/cm2) treatment. The levels of phospho-Thr308-Akt, phospho-Ser473-Akt, and total Akt were detected with western blot analysis at
indicated times. (D) Quantitative analysis of the levels of phospho-Thr308-Akt and phospho-Ser473-Akt in treated cells. (n = 4; *P <0.05 and
**P <0.05 versus corresponding control cells, #P <0.05 versus indicated cells). (E and F) LPS-activated microglial cells pretreated with or without
wortmannin, API-2, or SMT (100 μM) for 1 h, followed by LLLT (20 J/cm2) treatment. (E) Total F-actin in primary microglia was stained using FITC-
phalloidin at the indicated times and measured as described in Materials and Methods. Data represent mean± SEM (n = 6). (F) Fluorescent images
of the distinct microglial phagocytosis in BV-2 cells. Merged beads (red) and F-actin (green) are displayed in yellow (bottom). Images shown are
representative of approximately 100 cells. Bar = 10 μm. LLLT, low-level laser therapy; LPS, lipopolysaccharide.
Figure 7 Correlations between inflammatory mediators and the phagocytic response induced by LLLT in LPS-activated microglial.
(A and B) LPS-activated BV-2 cells pretreated with or without 200 μM carboxy-PTIO. Then the cells with or without LLLT (20 J/cm2) treatment
were incubated with microspheres for 30 min. (A) Quantification of LLLT-mediated microglial phagocytosis. (B) Number of microspheres taken up
per BV-2 cell. (n = 4; *P <0.05 versus control cells). (C and D) SH-SY5Y cells cultured with LPS-activated BV-2 cells or primary microglia (at an E:T
ratio of 8:1) in a Transwell™ cell-culture system or directly in the mixed co-culture system for 24 h. After incubation, target cells that were doubly
positive for CFSE and PI were analyzed by flow cytometry (n = 4; *P <0.05 and **P <0.05 versus indicated cells). CFSE, carboxyfluorescein diacetate
succinimidyl ester; LLLT, low-level laser therapy; LPS, lipopolysaccharide; PI, propidium iodide.
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Excessive accumulation of NO has long been known
to be toxic to neurons [51]. Oxygen-free radicals such as
superoxide can react with NO to form deadly intermedi-
ates such as peroxynitrite. Our results indicated that
LLLT could efficiently reduce LPS-activated microglia-
induced iNOS (Figures 1D and 2C) by downregulating
TLR-triggered proinflammation (Figure 2D - I).
How does LLLT activate Src? One of the most plausible
explanations is that LLLT activates Src through reactive
oxygen species (ROS). LLLT has been demonstrated to
increase the level of intracellular ROS generation [52].
With LLLT treatment, light is absorbed by endogenous
photosensitizers (porphyrins or cytochromes) that dom-
inantly locate at plasma membrane, mitochondria or
lysomes. The photosensitizers’ activation results in ROS
(1O2, O2
- , and H2O2) production [53]. Intracellular
oxidants could mediate the activation of Src [54].
This hypothesis was also supported by our previous
work [21]. Although there may be many other contri-
butors responsible for LLLT-mediated neuroprotective
effect, our experimental results suggest that Src and
Syk are primary participants in downregulation of
TLRs-triggered neuroinflammatory signaling pathway
(Figures 2 and 3).
The deposition of Aβ in the extracellular space of the
brain plays an important role in microglial activation in
AD. Although the role of microglia-mediated inflamma-
tion in the pathogenesis of AD is obvious, microglia
have been reported to mediate the clearance of Aβ
through receptor-mediated phagocytosis, which could
delay the progression of AD.
Recent studies suggested that Aβ oligomers could
induce a potent inflammatory response and subse-
quently disturb microglial phagocytosis and clearance of
Aβ fibrils, thereby contributing to an initial neurodegen-
erative characteristic of AD [26]. To address whether
LLLT-mediated anti-inflammatory effects can improve
microglial phagocytosis, we investigated the microglial
phagocytic activity after LLLT treatment. Phagocytic
activity of the LPS-activated microglia was markedly
enhanced after LLLT treatment (Figures 3 and 6). Fur-
thermore, LLLT could also activate the PI3K/Akt signal
pathway (Figure 5), which was dependent on Src acti-
vation under LLLT treatment. Since phagocytosis is a
Rac1-mediated actin-based process, our results demon-
strated that not only the activity of Rac1 but also the
F-actin accumulation were increased by PI3K/Akt after
LLLT. A constitutively active form of Rac1 greatly
increased F-actin polymerization, while a dominant
negative form of Rac1 inhibited F-actin polymerization
under LLLT treatment (Figure 5B). Thus, these results
suggested that LLLT-induced Src activation could also
improve microglial phagocytic activity by PI3K/Akt/
Rac1 signal pathway.
Activation of the PI3K/Akt signaling pathway has been
correlated with tumor metastasis and invasion [55]. In-
deed, PI3K is a key signaling molecular for integrin acti-
vation and regulation of actin reorganization [56]. The
nonreceptor tyrosine kinase FAK-Src complex can initi-
ate a cascade of phosphorylation events to trigger mul-
tiple intracellular pathways, including MAPK/ERK and
PI3K/Akt signaling [57,58]. In this study, using LPS-
activated BV-2 cells, we found that LLLT-mediated anti-
inflammatory effect did not require FAK. One of the
most plausible explanations of the above results is that
Syk activation does not require actin polymerization
since it is unaffected by inhibitors such as cytochalasin
D, whereas FAK activation requires actin polymerization
[59,60]. Thus, activation of Syk, but not FAK, plays a key
role in Src-mediated anti-inflammatory signal under
LLLT. However, inhibition of FAK by transfecting BV-2
cells with FRNK, a naturally occurring inhibitor of FAK
signaling, contributed to partial inhibition of microglia
phagocytosis.
FAK translocation between cytosolic and membrane is
highly regulated by many factors, including tyrosine
phosphorylation and actin assembly [61]. Since p85 was
associated with FAK to further activate Akt by binding
to tyrosine phosphorylated residue 397 of FAK [62], this
may explain why FAK could also be activated before
actin polymerization and only had partial effects on Src-
mediated microglial phagocytosis. Our results suggest
that LLLT-induced phagocytic activity depends on Src-
mediated PI3K/Akt signaling pathway, partially due to
the phosphorylation of FAK.
Microglial activation is considered as a hallmark of
AD. Alternatively, microglial activation is usually asso-
ciated with marked increase in CD11b expression [63].
Integrin CD11b/CD18 (macrophage antigen complex 1,
MAC1, also known as complement receptor 3, CR3) is
essential for the phagocytosis of multiple compounds
and mediates the activation of phagocytes in response to
a diverse set of stimuli [64]. The MAC1 receptor is
located on microglia, suggesting its role in neurodegen-
eration. In addition, previous reports indicated that
MAC1 might be a key receptor for Aβ to activate micro-
glia to produce extracellular superoxide, resulting in
neurotoxicity [65]. Conversely, others indicated that
ROS was a key player in microglial activation in which
ROS increased microglial expression of CD11b via NO
[66]. In fact, a recent study showed that activation of
CD11b via inside-out signaling negatively regulated
TLR-triggered proinflammatory response [20].
It is important to note that the role of microglial acti-
vation in AD is still debated, and a simplistic view of
microglia as solely beneficial or detrimental cells does
not reflect the complexity of microglial function [67].
Functionally, microglia react in diverse ways: they
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secrete inflammatory mediators, proteolytic enzymes or
neurotrophic factors, and are also able to take up soluble
and insoluble molecules. Hence, the ideal microglia-
targeted AD treatment modalities should not only focus
on microglial neurotoxic characteristics, but also on the
phagocytic activity.
However, in this study, we used human neuroblastoma
SH-SY5Y as the target neuronal cells to mimic responses
of inflammation-mediated neurotoxicity. Given that
microglia may have recognized markers of malignancy,
our results need to be further confirmed using primary
cortical neurons in the future studies.
Taken together, the current investigation demonstrates
that LLLT can inhibit LPS-activated microglia-induced
neurotoxicity and enhance its phagocytic activity
through activation of non-receptor tyrosine kinase Src.
Although cultured mouse microglia and its treatment
with etiological reagents may not truly resemble micro-
glia in the brain of patients, our results suggest that tar-
geting Src may be an important step for the attenuation
of microglial activation. Better understanding of the
regulation mechanism of activated microglia may pro-
vide a therapeutic strategy to control the progression of
neurodegenerative diseases.
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